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ABSTRACT 
 
Objective: To evaluate the clinicopathological features, response to treatment and 
outcomes in children presenting to Chris Hani Baragwanath Academic Hospital with biopsy 
proven minimal change nephrotic syndrome. 
 
Methods: A retrospective record review was conducted. Available records of children, 
between the ages of 1 and 14 years, who had nephrotic syndrome clinically and who were 
proven to be minimal change nephrotic syndrome on renal biopsy, were studied. Children 
who presented from January 1996 to December 2010 were included. Their demographics, 
clinical features on presentation, biopsy results, management and outcomes were studied.  
 
Results: In the 15 year period there were 129 (29% of all NS) children with minimal change 
nephrotic syndrome. Seventeen patients were excluded because 4 were not biopsied and 
13 patients’ records could not be traced. The remaining 112 patients were included in the 
study. Ages ranged from 1 year to 13.6 years with a median age of 3.8 years (IQR 2.6-5.9). 
There was a male predominance, with 72 males and 40 females (1.8:1). The majority of the 
children studied were Black African (89.3%). On presentation 68.8% had microscopic 
haematuria. Although 59.8% had a blood pressure at presentation which was above the 
95th centile for gender, height and age, only 33.9% had sustained hypertension. On initial 
biopsy, 34% were found to have the mesangial hypercellular variant of minimal change 
disease and 6% had the IgM variant of minimal change disease. Two patients went into 
spontaneous remission. The remainder, were treated with oral corticosteroids. Of those 
treated, 58.9% were steroid responsive, 19.6% were steroid resistant and 8.9% were 
initially responsive but subsequently became steroid resistant. Of the sample, 22.3% were 
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steroid dependent and 16.1% were frequent relapsers. Second line immunosuppressive 
therapy was needed in 38 (33.9%) patients. The three second line immunosuppressant 
agents used were intravenous pulsed cyclophosphamide (28.5%), intravenous pulsed 
methyl prednisolone (9.8%) and mycophenolate mofetil (MMF) (7.1%). Repeat biopsies 
were performed on 22 children (19.6%). Four of the 22 repeat biopsies showed focal 
segmental glomerular sclerosis (FSGS).The average length of follow up was 4.86 years 
(median 3.58). At the last visit, 75.9% of the study group was in remission. During the 
course of follow up, 41.1% were admitted to hospital for a suspected bacterial infection. A 
high proportion of patients were lost to follow up (62%). The mortality rate was 1.8%. 
  
Conclusion: At Chris Hani Baragwanath Academic Hospital, all children with nephrotic 
syndrome are biopsied prior to initiating steroid therapy due to the high prevalence of 
tuberculosis infection and poor compliance in our population. This practice has highlighted 
differences between the children in our population with minimal change disease compared 
to that reported by the International Study of Kidney Disease in Children (ISKDC). In our 
study there were a higher proportion of children with initial hypertension and haematuria, 
and fewer children that responded to steroid therapy. This differs from the ISKDC findings in 
1978. Their study had predominantly Caucasian children, and our study had predominantly 
Black African children. These differences in ethnicity may account for the differences. 
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CHAPTER 1. LITERATURE REVIEW 
 
1.1 Historical Perspective  
 
Nephrotic syndrome is one of the commonest causes of renal disease in children (1). 
Proteinuria as a cause of oedema was recognized by Hippocrates over 2000 years ago (2). 
There were many other descriptions of nephrotic syndrome over the years (2) and in 1929 
Henry Christian introduced the term nephrotic syndrome (1). Previously, many patients with 
nephrotic syndrome developed chronic renal failure or died from infections, but a few 
improved spontaneously (3). With the introduction of various antibiotics the mortality rate 
dropped from 48% to 19% (4). With the use of corticosteroids it has dropped further to 9% 
(5). The ISKDC (International Study of Kidney Disease in Children) reported a mortality rate 
of 2.5% post corticosteroid era in children with minimal change nephrotic syndrome (6). 
 
Initially, the management of nephrotic syndrome was focused on treating the oedema (4). 
Mercury containing agents were used as a diuretic (4). These compounds are nephrotoxic 
and their use was discontinued (3). Later, induction of measles (4) and malaria (5) were 
used to treat nephrotic syndrome. Infusion of albumin was used to correct the albumin and 
treat the oedema, and diuretics were used to help control the oedema (7). The use of ACTH 
therapy and later cortisone significantly improved outcomes in nephrotic syndrome (8, 9). 
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1.2 Definition of nephrotic syndrome  
 
Nephrotic syndrome is characterized by heavy proteinuria (>40mg/m2/hour), oedema, 
hypoalbuminaemia and hyperlipidaemia (1). It is divided into congenital, idiopathic (primary) 
and secondary nephrotic syndrome (7). Congenital or infantile nephrotic syndrome, 
presenting before 1year of age, has a poorer prognosis and is caused by certain gene 
mutations affecting components of the glomerular filtration barrier (10). Secondary nephrotic 
syndrome is due to an underlying systemic disease such as systemic lupus erythematosus, 
IgA Nephropathy, HIV associated nephropathy and diabetic nephropathy (7). Idiopathic 
nephrotic syndrome is the largest group. It includes; minimal change disease (MCD), focal 
segmental glomerular sclerosis (FSGS) and diffuse mesangial proliferation (10, 11). Some 
authors consider these 3 different types to be part of the same spectrum of disease, 
however, other authors feel that they are distinct entities (10). Membranous nephropathy is 
also included in idiopathic nephrotic syndrome (12). Most patients with idiopathic nephrotic 
syndrome have minimal change disease (13). 
 
1.3 Epidemiology of nephrotic syndrome 
 
The prevalence of idiopathic nephrotic syndrome is about 16 per 100 000 population (14). 
The incidence varies amongst different populations and seems to be higher in children of 
African and Asian descent (15). There is an overall male predominance with a male to 
female ratio approaching 2:1 in younger children (15). Many studies have shown ethnic 
differences in histological types and response to treatment (11, 16, 17). Internationally, as 
reported by the ISKDC in 1978, the majority of children (77%) with primary nephrotic 
syndrome had minimal change nephrotic syndrome (MCNS). They also found that 93% of 
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children with MCNS were steroid responsive and, MCNS could be identified by typical 
clinical features at presentation such as: absence of haematuria or hypertension, age of 
presentation younger than 6 years but older than 1 year, normal C3 level, and normal renal 
function, together with responsiveness to steroid therapy. (13) In South Africa, studies have 
shown that MCNS is not the commonest histological type of nephrotic syndrome in Black 
African children. However, Indian and Caucasian children from South Africa seem to follow 
what was described by the ISKCD. (18-20)  
 
1.4 Minimal Change Disease 
 
1.4.1 Aetiology  
 
There has been a lot of research into the underlying cause of idiopathic nephrotic syndrome 
(INS) in the last few decades. Researchers are looking to identify the underlying cause and 
thus, facilitate the development of better, targeted therapeutic agents. (21) There are many 
theories but no one cause has been identified. Some researchers feel there is an immune 
abnormality related to T cell dysfunction (3). Others suggest that there may be circulating 
factors that cause injury to the podocytes (21-23). There is also research into genes that 
code for certain proteins like nephrin and podocin that have been implicated in certain forms 
of steroid resistant nephrotic syndrome (24). 
                                                                                                                                                                                                                                                                 
  
 4 
1.4.2 Presentation  
  
The majority of children with MCNS will present before the age of 6 years (13). They have 
the typical features of nephrotic syndrome; oedema, proteinuria, hypoalbuminaemia and 
hyperlipidaemia. They are often intravascularly depleted in the face of severe oedema. (6)  
These children may have respiratory compromise secondary to pleural effusions or 
pulmonary oedema. Some children may have complications such as venous thrombosis or 
severe sepsis at presentation. (12) According to the ISKDC, in children with MCNS, only 
23% have haematuria at presentation and 21% have a high blood pressure at presentation 
(13). In a previous study from Johannesburg it was found that 84% of children with MCNS 
had microscopic haematuria at presentation and 13.4% had hypertension (25). Children 
with MCNS generally have normal renal function or mild pre-renal dysfunction. They also 
have high cholesterol and triglyceride levels, which generally resolves once the child is in 
remission. (26)  
 
1.4.3 Histological findings  
 
In the majority of children with MCD there are normal glomeruli with no abnormalities on 
light microscopy and foot process effacement on electron microscopy (27). Some patients 
may have mild mesangial hypercellularity which is regarded as a variant of MCD (28). 
Some studies report that this variant may have a poorer prognosis but others have failed to 
confirm this (27, 28). IgM nephropathy is another variant of MCD with mesangial IgM 
deposits associated with either minimal change or mesangial hypercellularity. This variant 
has been shown to have a poorer prognosis and a higher rate of steroid dependence and 
steroid resistance when associated with mesangial hypercellularity. MCNS with IgM 
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deposits and no mesangial hypercellularity, has been shown to behave the same as 
minimal change disease.(29-31) Some authors argue that these are separate entities and 
not variants of MCD due to the differences in presentation and outcome (27, 32) 
 
1.4.4 Treatment 
 
Based on the results from the ISKDC, the current recommendations (33) are that in children 
with nephrotic syndrome, once secondary causes have been ruled out (by detailed history, 
examination and blood results) and the presentation is typical of MCD (no haematuria, 
normal blood pressure, normal C3 and age between 1 and 6 years (13)), then a trial of 
steroids should be started with no need for a renal biopsy. If the patient responds to 
steroids and does not have frequent relapses then they are presumed to have MCD (6) and 
treatment and follow up are continued as such.  
 
1.4.4.1 Symptomatic treatment 
 
A low salt diet and mild fluid restriction may be used to manage the oedema (26).  Protein 
intake should be slightly higher than age recommendations (10) with less saturated fat (26, 
34). Some children with MCD may need diuretic therapy to treat the oedema if it is severe, 
and albumin to treat the hypovolaemia (34). However, routine use of diuretics and albumin 
is not recommended due to the potential complications such as intravascular volume 
depletion, worsening renal function and electrolyte abnormalities with diuretics and 
congestive cardiac failure with albumin. (14, 26) 
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Dyslipidaemia does not require routine treatment as the levels return to normal once the 
child is in remission (26). However, in children with steroid resistant disease, the risk of 
atherosclerosis is increased and warrants dietary modifications and lipid lowering therapies 
such as HMG-CoA reductase inhibitors (14). 
 
Maintenance of normal intravascular volume, avoidance of bed rest and early recognition 
and management of infections are necessary to prevent the formation of thrombi (10). 
Routine use of anticoagulants for primary prophylaxis is not recommended (26, 34). Some 
authors suggest antiplatelet agents such as low dose aspirin may be useful in patients with 
steroid resistant nephrotic syndrome or underlying hypercoagulable states (14).  
 
Antihypertensive agents, such as calcium channel blockers or β adrenergic antagonists can 
be used to manage high blood pressure (34). For chronic hypertension however, 
angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers are 
preferred as they also decrease proteinuria (14, 26). 
 
Infections need to be treated early as they are an important contributor to morbidity (26). 
Antibiotics used should cover Streptococcus pneumoniae and gram negative organisms 
until culture results are available as these are the most commonly identified bacterial 
causes of sepsis (26, 34). There is no good evidence for prophylactic penicillin use (14) but 
some authors feel that there is still a place for prophylaxis due to the overwhelming number 
or infections caused by Streptococcus pneumoniae (26). Routine administration of the 
Influenza virus vaccine, the Varicella zoster virus vaccine and the Pneumococcal vaccine is 
important to prevent infections (26). In developing countries tuberculosis is an important 
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consideration as the rate of pulmonary tuberculosis is higher in children with nephrotic 
syndrome (35). Current recommendations from India state that children without evidence of 
tuberculosis and a positive Mantoux test should get 6 months of isoniazid therapy and those 
with evidence of active disease should be treated with standard regimens (34).  
 
1.4.4.2 Steroid therapy 
 
Initially, before corticosteroids became available, ACTH therapy was used to treat nephrotic 
syndrome and it improved outcomes in these patients (8). Corticosteroids were later 
introduced and they were thought to suppress an immune mediated process that was 
damaging the glomerular filtration barrier (24). Recent studies have shown that steroids 
actually affect podocyte function directly (3, 21, 24).  
 
Based on the ISKDC recommendations, subsequent studies done by the 
Arbeitsgemeinschaft fur Padiatrische and various Cochrane reviews, the current 
recommended schedule is 2mg/kg/day (maximum 60mg) of prednisone for 4 - 6 weeks 
followed by 1.5mg/kg (maximum 40mg) every alternate day with weaning of the dose over 2 
to 5 months.(14, 33, 36) 
 
Based on the regimen suggested by Mendoza for the treatment of steroid resistant 
nephrotic syndrome due to FSGS (37), pulsed intravenous methyl prednisolone has been 
used together with intravenous cyclophosphamide to induce remission in steroid resistant 
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nephrotic syndrome with MCD, as well (38). The KDIGO guidelines however state that 
cyclophosphamide can be used in frequently relapsing and steroid dependent nephrotic 
syndrome(39), however, based on a Cochrane review of a few small randomized control 
trials, they recommend that cyclophosphamide not be used in steroid resistant nephrotic 
syndrome(40) as one study showed that cyclosporine achieved remission in more patients 
than cyclophosphamide and two studies showed that it was no more effective than steroids 
alone. These studies were all reported as having low or very low quality evidence due to 
various reasons, one of them being small numbers. (41) 
  
1.4.5 Complications 
 
Complications of nephrotic syndrome are well documented (1, 10, 12). They are divided into 
complications of the disease and complications of treatment. Some complications are 
caused by both the disease process and the treatment.  
 
1.4.5.1 Infections 
 
Children with nephrotic syndrome are predisposed to infections because of the disease 
itself and the various treatment modalities that affect the immune system. The commonest 
infections are peritonitis, cellulitis, pneumonia and urinary tract infections. (14, 26, 34)  
Respiratory tract infections, which are usually viral, and urinary tract infections are the 
commonest infections which trigger a relapse (42). Prompt treatment of infections and 
appropriate adjustment of steroid therapy is necessary during these episodes (36, 42). 
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1.4.5.2 Thrombosis 
 
There is an increased incidence of venous and rarely arterial thrombosis in children with 
nephrotic syndrome (14, 26). There are multiple reasons why children with nephrotic 
syndrome are at increased risk for development of thrombi. Hypovolaemia and increased 
blood viscosity, hyperlipidaemia, immobility, loss of anticoagulant proteins and side effects 
of the medication all contribute to the risk of thrombosis formation. (12, 26)  
 
1.4.5.3 Dyslipidaemia 
 
At presentation children with nephrotic syndrome have raised cholesterol and triglyceride 
levels. This improves without treatment once they go into remission. (26) Children with 
steroid resistant nephrotic syndrome have persistent dyslipidaemia and may need HMG 
CoA reductase inhibitors to treat the dyslipidaemia (14). 
 
1.5 Aims and Objectives 
 
1.5.1 Aims 
 
To determine the profile of paediatric patients presenting to Chris Hani Baragwanath 
Academic Hospital with Minimal Change Nephrotic Syndrome over a 15 year period. 
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1.5.2 Objectives 
 
a. To determine the percentage of children presenting with nephrotic syndrome who 
have minimal change disease on renal biopsy. 
b. To describe the demographics of children with minimal change disease. 
c. To determine the rate of response to steroid therapy, dependence on steroid therapy 
and the need for additional immunosuppressive therapy. 
d. To ascertain whether there is an association between variants on light microscopy 
and immunofluorescence staining (mesangial hypercellular variant and IgM 
nephropathy) and failure to respond to steroid therapy. 
e. To determine the rate of focal segmental glomerulosclerosis on repeat biopsy. 
f. To determine the length of follow up and the outcome of these patients. 
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CHAPTER 2: METHODS 
 
2.1 Study Design 
 
A retrospective record review was conducted. Records of patients who presented to the 
Nephrology Unit at Chris Hani Baragwanath Academic Hospital between January 1996 and 
December 2010 were analysed. Data was collected from the Nephrology Clinic files and 
some missing data was collected from inpatient files and laboratory records.  
 
2.1.1 Inclusion criteria 
 
All children aged 1 year to 14 years presenting to Chris Hani Baragwanath Academic 
hospital with nephrotic syndrome who were proven to have minimal change disease on 
biopsy were included. 
 
2.1.2 Exclusion criteria 
 
Patients with suspected nephrotic syndrome who did not consent to biopsy or those who 
were not biopsied for other reasons were excluded. Those with inadequate biopsies were 
also excluded.  
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2.2 Ethics  
 
The University of the Witwatersrand Ethics Committee granted ethics approval 
unconditionally at a meeting on 4th May 2012 (clearance certificate M120468 – Appendix A). 
All patients were allocated a study number and their names and hospital numbers were not 
recorded on the data collection sheet.  
 
2.3 Data collection and analysis 
 
Data was collected manually on the data collection sheet and then captured into Microsoft   
Excel (see Appendix B for data collection sheet). All descriptive statistics such as means, 
medians, frequencies, percentages as well as standard deviations and interquartile ranges 
were obtained using Microsoft Excel. Graphs such as pie charts, frequency distribution 
tables were drawn in Microsoft Excel. The remaining statistical analysis was done using 
Statistica. Chi-squared, Fisher exact and ANOVA tests were used to determine 
significance. Statistical significance was measured at a level of 5% (p-value<0.05). 
 
2.4 Definitions of outcomes measured 
 
High blood pressure on presentation was determined using age, gender and length or 
height centiles according to charts published in the fourth report on the diagnosis, 
evaluation and treatment of high blood pressure in children and adolescents from 2004 
(43). A blood pressure above the 95th centile was assessed as high. 
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Haematuria was regarded as significant if there was 1+ or more red blood cells detected on 
urine dipstick. This was based on recommendations of significant microscopic haematuria 
from a British research group. Formal urine microscopy is more reliable than urine dipstick 
findings. (44) However, the results of formal urine microscopy, to assess number of red 
blood cells per high power field, red cell morphology and the presence of casts, was not 
available on most patients and thus not included in the study.    
 
The glomerular filtration rate (GFR) was calculated using the modified Schwartz bedside 
calculation (GFR = 0.413 x height (cm) / serum creatinine (mg/dl) or GFR = 36.5 x height 
(cm) / serum creatinine (µmol/l)) (45, 46)  
  
Response to treatment was defined as follows: (6) 
 Remission – trace or 1+ protein on urine dipstick for 3 consecutive days with 
resolution of oedema 
 Responded – went into remission within 8 weeks of daily, high dose steroid therapy 
 Resistant (non-responder) – not in remission after 8 weeks of high dose steroid 
therapy 
 Initially responsive then resistant (late non-responder) – initially went into 
remission within 8 weeks but later relapsed and did not respond to steroids 
 
Outcomes were defined as follows:  (6, 33) 
 Steroid sensitive nephrotic syndrome: responds to corticosteroids by achieving 
complete remission. 
 Frequent relapsing nephrotic syndrome: has 2 or more relapses in the first 6  
months or 4 or more relapses in a 12 month period 
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 Steroid dependent: responded to treatment but relapses on weaning steroids or 
within 2 weeks of stopping steroids. 
 Transfer to adults: once patients were older than 14years they were eligible for 
transfer to adult nephrology services. 
 Death: The patient demised during follow up. 
 Loss to follow up: patients who did not return for follow up at any point in the 
course of follow up  
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CHAPTER 3: RESULTS 
 
3.1 Patient characteristics at presentation 
 
3.1.1 Study population and demographics 
 
The study included patients that presented to the Paediatric Nephrology Unit from January 
1996 to December 2010. Only patients with biopsy proven minimal change disease were 
included.  
 
During this 15 year period there were a total of 440 children with idiopathic nephrotic 
syndrome. Of these 129 (29%) patients had minimal change nephrotic syndrome, 4 of these 
patients were not biopsied and 13 patients’ records could not be traced. The remaining 112 
patients were included.  
 
Figure 1: Study Sample 
 
129 MCNS (over 15years) 
 
4 not biopsied   125 biopsied 
 
13 no records found   112 included 
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The table below shows the demographics of the patients included in the study.  
Table 1: Demographics of patients with MCNS  
 
Total Number 112 
Age - range (years) 1 to 13.6 
        - median (IQR) 3.8 (2.6 to 5.9) 
Gender -  Males 72 (64.3%) 
              -  Females 40 (35.7%) 
Race - Black African 100 (89.3%) 
          - Caucasian 3 (2.7%) 
          - Mixed Race (Coloured) 4 (3.6%) 
          - Indian 5 (4.5%) 
 
 
The age of patients ranged from 1 year to 13.6 years with and interquartile range of 2.6 to 
5.9 years. The figure below shows the age distribution of the study sample. 
 
Figure 2: Age distribution of children in the study (n=112) 
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The majority of the patients that present to CHBAH are Black African. A small number of 
Caucasian, Indian and Mixed Race (Coloured) patients also presented to the unit. 
 
Figure 3: Race of patients with minimal change disease (n = 112) 
 
 
There was a male predominance with a male : female ratio of 1.8:1. 
 
Figure 4: Gender of patients with minimal change disease (n=112) 
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3.1.2 Blood pressure at presentation 
 
The mean systolic blood pressure was 108mmHg (standard deviation = 15mmHg). At 
presentation 59.8% (67) had a high blood pressure (either systolic or diastolic that was 
above the 95th centile for gender, age and height). On follow up only 38 patients (33.9%) 
had hypertension and needed treatment. There was no significant association between 
blood pressure at presentation and biopsy results (p=0.17), response to treatment (p=0.25) 
or number of relapses (p=0.53). 
 
3.1.3 Urinalysis at presentation 
 
Urine dipstick analysis was performed on all patients at presentation. In 3 patients the result 
was not documented. Of the rest, 68.8% had 1+ or more haematuria on dipstick. When 
evaluating the association between haematuria and minimal change variants on biopsy 
there was no significant difference (p=0.69). There was also no significant association 
between haematuria at presentation and response to steroids (p=0.79) or number of 
relapses (p=0.86).   
 
Figure 5: Microscopic haematuria on urine dipstick 
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 3.1.4 Blood results on presentation 
 
Serum cholesterol, albumin, urea and creatinine on presentation were analyzed. The 
cholesterol levels were very high with a median of 11mmol/l (IQR 8.4 – 13.4). Eighty-eight 
percent of the study sample had a total cholesterol level above 6.4mmol/l(250mg/dl) at 
presentation. The urea levels were closer to the upper limit of normal with a median of 
4.2mmol/l (IQR 2.8 – 5.6). The creatinine levels however were mostly normal with a normal 
estimated GFR as demonstrated in the table below.  
 
Table 2: Creatinine and estimated GFR  
 
 Median Interquartile Range 
Creatinine(µmol/l) 34 27 – 44  
GFR (ml/min/1.73m2) 105 87 – 145 
 
 
3.1.5 Urine results on presentation 
 
Only a spot urine specimen was sent for urine analysis. A protein : creatinine ratio was 
done on these specimens. The median was 1.04 g/mmol (IQR 0.64–1.73). Twenty-four hour 
urine specimens were not sent, therefore urine protein losses could not be quantified in 
terms of grams/day. 
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3.1.6 HIV and tuberculosis co-morbidity 
 
From the patients included in the study, 78.6% were HIV negative. The remaining 21.4% 
did not have a documented HIV results. There were no known HIV infected children in this 
study. 
 
Fourteen patients had a positive Mantoux tuberculin skin test. Of the remainder, 17 did not 
have a tuberculin skin test result documented and the rest (81) had no reaction or a 
reaction smaller than the recommended cut off. Anti-tuberculosis treatment was started on 
25 patients (22.3%). 
 
Figure 6: Tuberculin skin test results 
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3.2 Renal biopsy results 
 
3.2.1 Initial biopsy 
 
All the patients were biopsied at presentation. In one patient, the initial biopsy was 
inadequate and a repeat was done a few weeks later. All specimens were sent for light 
microscopy, immunofluorescence staining and scanning electron microscopy. Of the 112 
patients, 54% (61) did not have electron microscopy performed because the pathologist felt 
the light microscopy and immunofluorescence were conclusive.  
 
The results of the initial biopsies are shown in the table below. Just under half of the 
patients had a variant of minimal change disease. The commonest variant was the 
mesangial hypercellular variant. There were only 7 patients with IgM nephropathy. 
 
Table 3: Biopsy results 
  
Initial Biopsy (112) Number Percentage 
Minimal Change 67 60% 
Mesangial hypercellular variant 38 34% 
IgM nephropathy 7 6% 
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3.2.2 Repeat biopsies 
 
Repeat biopsies were performed in 22 children. Eighteen of the 22 had either steroid 
resistant, steroid dependent or frequently relapsing nephrotic syndrome. The other 4 did not 
fit any of the above definitions but were difficult to wean off steroid therapy. There was no 
difference in the median length of initial steroid therapy between the initial cohort and those 
requiring repeat biopsies. The results of the repeat biopsies are shown in the table below. 
Only 4 patients with repeat biopsies showed progression to FSGS. 
 
Table 4 : Repeat biopsy results 
 
 
 
 
 
 
3.3 Treatment 
 
3.3.1 Steroid therapy 
 
3.3.1.1 Oral corticosteroids 
 
Oral corticosteroid therapy was commenced once the biopsy results were obtained in 98% 
(110) of the patients. The remaining 2 patients had gone into spontaneous remission prior 
Repeat (22) Number Percentage 
Minimal Change 10 45.4% 
Mesangial hypercellular variant 8 36.4% 
FSGS 4 18.2% 
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to the initiation of steroids. The initial dose of oral prednisone used was 2mg/kg/day as a 
daily dose up to a maximum of 60mg per day. The median duration of daily high dose oral 
corticosteroids was 8 weeks (IQR 4 – 12). Once the patient was in the remission the dose 
was weaned to an alternate day dose.  
 
3.3.1.2 Intravenous methylprednisolone 
 
In 9 patients, high dose, pulsed, alternate day intravenous methylprednisolone was used to 
induce remission in steroid resistant nephrotic syndrome. In 8 of these patients it was 
followed by intravenous pulsed cyclophosphamide therapy. 
 
3.3.2 Adjunctive therapy 
 
3.3.2.1 Anti-tuberculosis treatment 
 
Treatment for pulmonary tuberculosis was started in 25 patients based on symptoms 
together with either chest X-ray findings or tuberculin skin test results.  
 
3.3.2.2 Spironolactone 
 
Most patients (83%) were started on spironolactone therapy. Spironolactone therapy is 
used by our renal unit for its diuretic effects and for its effect on preventing renin driven 
sodium and water retention. 
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3.3.2.3 Antiplatelet agents 
 
Antiplatelet agents such as aspirin or dipyridamole were used in 93 (83%) patients for 
primary prevention of thromboembolic complications. Initially dipyridamole was preferred.   
  
3.3.2.4 Lipid lowering agents 
 
Statins were used in 26 patients (23%). Of the 26 children that were started on lipid 
lowering agents, 11 were either steroid resistant, steroid dependent or frequent relapsers. 
 
3.3.2.5 Antihypertensive agents 
 
ACE Inhibitors were used in 45 (40%) patients. It was used to treat hypertension and to 
decrease proteinuria in steroid resistant patients. 
 
3.3.3 Second line immunosuppressant agents 
 
During the study period only 2 second line agents were used. A total of 34 patients required 
a second line agent. Twenty of the 34 were resistant to steroid therapy, 11 were steroid 
dependent and/or frequent relapsers. The remaining 3 patients were labelled as either 
steroid dependent or frequent relapsers, but did not fit the definition per se. In 32 patients, a 
pulsed, monthly dose (500mg/m2/dose) of intravenous cyclophosphamide was used for 6 
months. In 6 of those 32 patients mycophenolate mofetil (MMF) was added if they did not 
respond to the oral corticosteroids and intravenous cyclophosphamide. In 2 patients MMF 
was used alone as a second line immunosuppressant agent. In our unit intravenous 
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cyclophosphamide is preferred to oral cyclophosphamide as compliance is a problem in our 
patient population. A monthly intravenous dose, results in better compliance, and we have 
noted minimal side effects. 
 
3.4 Outcomes 
 
The flow diagram below shows the outcomes according to biopsy results. 
 
Figure 7: Flow Chart of outcomes according to histological variants 
 
Spont – went into spontaneous remission 
SSNS – Steroid sensitive nephrotic syndrome 
SRNS – Steroid resistant nephrotic syndrome  
Bx only – only initial presentation and biopsy results are available (there is no follow up data)    
 
 
There was no significant difference in the response to steroid treatment, between the 
minimal change group and the mesangial hypercellular variant group (p=0.62). The IgM 
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nephropathy variant had a poorer response to treatment with 43% being steroid resistant 
but this difference is not statistically significant (p=0.67), possibly, due to the small number 
in that subset. 
 
3.4.1 Response to steroid therapy                
 
Seventy-six patients (67.8%) initially responded to steroids, 10 of the 76 later became 
steroid resistant. Twenty-two patients (19.6%) were resistant to steroids initially. Two 
percent went into spontaneous remission. The remainder defaulted follow up and their initial 
response to steroid therapy is unknown. There were 25 patients (22.3%) that had steroid 
dependent nephrotic syndrome. On follow up 16 of the 25 remained steroid dependent at 
their last visit. Overall at the end of follow up, 59% of patients had steroid sensitive 
nephrotic syndrome and 28.5% of patients had steroid resistant nephrotic syndrome.  
 
3.4.2 Duration of steroids 
 
The median duration of steroid treatment was 8 weeks with an interquartile range of 4 to 12 
weeks. There was a significant association between a shorter duration of initial steroid 
therapy and developing frequently relapsing nephrotic syndrome (p=0.021) 
 
3.4.3 Relapses 
 
Of the 112 patients in the study, 64 had at least 1 relapse. The median number of relapses 
was 1. The highest number of relapses was 18 in 1 child. Overall, 18 patients (16%) had 
frequently relapsing nephrotic syndrome.  
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3.4.4. Response to Intravenous Cyclophosphamide and MMF 
 
Of the 32 patients treated with cyclophosphamide, 23 responded and went into remission. 
Eleven of the twenty-three continued to have multiple relapses and some remained steroid-
dependent. Only 9 patients (28%) did not respond to cyclophosphamide. Six of these nine 
patients had repeat biopsies done. Two showed FSGS, one showed mesangial 
hypercellular variant, one showed IgM nephropathy with mesangial hypercellularity and two 
showed minimal change only. 
 
Of the 8 patients treated with MMF, 6 had steroid resistant nephrotic syndrome and 2 had 
steroid dependent nephrotic syndrome. Only 2 of the 6 patients with steroid resistant 
nephrotic syndrome went into remission.   
 
3.4.5 Complications 
 
3.4.5.1 Admission for Infections 
 
During the course of follow up, 46 (41%) patients required admission for treatment of a 
suspected bacterial infection. These infections included peritonitis, pneumonia, septicaemia 
and urinary tract infections. Two of these patients died during their admission from sepsis 
related complications. These were the only 2 known deaths that occurred in the study 
population. 
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3.4.5.2 Chronic Kidney Disease 
 
Three patients developed chronic kidney disease during follow-up. Two of these patients 
had steroid resistant nephrotic syndrome but repeat biopsies were not done. The third 
patient had a repeat biopsy, due to steroid resistance, which showed FSGS.  
 
3.4.5.3 Hypertension 
 
As mentioned before 34 % of the patients had hypertension requiring treatment.   
 
3.4.5.4 Death 
 
There were 2 known deaths in the study population. The one had IgM nephropathy and was 
a frequent relapser. He died 5years and 4 months after presentation. At the time of his 
death he was admitted for streptococcal septicaemia. The second child also died from 
sepsis. She was steroid resistant and had developed renal failure. She died a year and 2 
months after presentation.   
 
3.4.6 Follow up 
 
The median duration of follow up was 3.6 years (IQR 0.7 to 7.7 years). There was a 62% 
(69) loss to follow up. Thirty-two of the 69 patients (29% of the total) defaulted within the 
first year, of those 12 (11% of the total) were started on steroids but never returned after the 
biopsy. Seven patients were transferred to the adult nephrology services and 4 patients 
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were transferred to other hospitals. The remaining 40 patients still attend the Paediatric 
Nephrology Clinic at CHBAH. 
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CHAPTER 4: DISCUSSION  
 
4.1 Background 
 
Idiopathic nephrotic syndrome is the commonest form of nephrotic syndrome in children 
(12). The majority of children with idiopathic NS have minimal change disease on biopsy 
and most children with MCD have a favourable response to steroid therapy (3, 13). 
Congenital or infantile nephrotic syndrome is usually genetic in origin (10) and thus children 
under the age of 1 year were excluded from this study. 
 
The present study differs from other studies as only patients with biopsy proven minimal 
change nephrotic syndrome were included. Most recent studies on nephrotic syndrome in 
children, either study idiopathic nephrotic syndrome in general, steroid sensitive nephrotic 
syndrome (presumed to be MCD) or steroid resistant nephrotic syndrome (15-17, 47-50). 
International practice, based on current recommendations, is not to routinely biopsy children 
who are steroid sensitive, with typical features of MCD. (33, 47) The current practice at 
Chris Hani Baragwanath Academic hospital is to biopsy all children presenting with 
nephrotic syndrome prior to the initiation of treatment due to the high prevalence of 
tuberculosis, poor compliance and higher rates of steroid resistance. This puts us in a 
unique position. We are able to describe MCD in our population and see how it differs from 
the population group described by the ISKDC study (13). It does, however, make the 
comparison between our findings and recent literature very difficult.  
 
In a predominantly Caucasian and Asian population, the internationally reported proportion 
of children with nephrotic syndrome who have MCD is 77% (13). However in a mixed 
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population with more African-American and Hispanic patients the proportion is much lower 
(55% presumed and biopsy proven) (11). Even in a European population from Croatia, the 
proportion of children with nephrotic syndrome, who had presumed or biopsy proven MCD 
was 53.5% (49). In the period studied (1996 – 2010), MCD only made up 29% (129/440) of 
all children presenting to Chris Hani Baragwanath Academic hospital with nephrotic 
syndrome. This hospital was the only hospital serving Soweto and its’ surrounding regions 
at the time of the study with the majority of the patients seen coming from this area. It is 
also a referral hospital to other level 1 and 2 hospitals in the southwestern parts of Gauteng 
and to the entire North West province. Thus there may be a slight selection bias but not 
enough to explain the massive difference in the proportion of children with nephrotic 
syndrome that have MCD. This difference may be a result of the difference in the ethnicity, 
and thus the genetics, between the children studied by the ISKDC study (Caucasian and 
Asian predominantly) (13) and our population (predominantly Black African) (11, 16, 17). 
 
4.2 Patient characteristics at presentation 
 
4.2.1 Demographics 
 
Our study population was predominantly African (89%) with just over 10% being made up of 
a combination of Caucasian, Indian and Mixed Race (Coloured) children. This is different to 
the population studied by the ISKDC group. Their population was predominantly Caucasian 
and Asian (13). Many authors have reported that ethnicity has an impact on the proportion 
of children with idiopathic nephrotic syndrome who have minimal change disease and their 
response to steroid therapy. (11, 16-18, 20, 50) This difference may explain the difference 
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in response to steroids and the higher percentage of steroid resistance and dependence 
seen in our population. 
 
Most studies have shown a clear male predominance in children with nephrotic syndrome 
(15-17, 20, 50). The male to female ratio in this study is 1.8:1 which is in keeping with that 
reported for children with minimal change disease by the ISKDC study (1.9:1) (13).  
 
The median age of children in this study is 3.8years (IQR 2.6 to 6years). This is similar to 
the figure reported by ISKDC study of 79% of children with MCNS presenting under the age 
of 6 years(13).  
 
4.2.2 Clinical features 
 
Based on published data from the ISKDC, certain clinical features are thought to be 
predictive of MCNS. These are: age of presentation after 1 year but before 6 years of age, 
absence of haematuria, normal C3, normal blood pressure and being steroid responsive. (6, 
13) In our study a high percentage (68.8%) of children presented with microscopic 
haematuria on urine dipstick. This is much higher than that reported in children with MCNS 
by the ISKDC group (23%) (13) but in keeping with a previous study done at the same 
hospital (25). Our study also showed a much higher percentage of children with a high 
blood pressure at presentation (59.8%) compared to the ISKDC population (20.7%) (13). 
This finding is not in keeping with a previous study from this same population group that 
reported a much lower percentage (13%) (25). This discrepancy is difficult to explain and is 
an area that needs to be investigated further. There is however a study from Germany that 
reports 95% of children with MCNS had a high blood pressure at presentation. The same 
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study also reported that only 19% remain hypertensive once in remission. (51) In our study, 
33.9% of patients were reported to be hypertensive on follow up. A review by Gipson et al 
reported that hypertension occurred in 13 to 51% of children with idiopathic nephrotic 
syndrome (14). 
 
Blood results on presentation showed a serum cholesterol level above 6.4mmol/l in 88% of 
patients. This is in keeping with the definition of nephrotic syndrome (1) and slightly lower 
than ISKDC report that 95% of children had a cholesterol level above 250mg/dl (6.4mmol/l) 
(13). Only 23% of patients needed a lipid lowering agent due to persistently high cholesterol 
levels. The American Association of Pediatrics recommends a low fat diet and treatment 
with a lipid lowering agent if the fasting LDL cholesterol is greater than 4.1mmol/l (26). 
Others recommend treatment with HMG CoA reductase inhibitors in children with steroid 
resistant nephrotic syndrome and persistent dyslipidaemia (14).   
 
Creatinine values and calculated GFR were normal in our study but urea values were mildly 
elevated suggesting mild intravascular volume depletion which can be present in children 
with nephrotic syndrome (26).  
 
The prevalence of HIV and tuberculosis is very high in Sub-Saharan Africa (52). In our 
study 22.3% of children with MCNS were started on treatment for tuberculosis. This is 
higher than the percentage of children with MCNS and tuberculosis reported in a previous 
study from Soweto (35). Gulati et al reported that 9%(28/300) of children with nephrotic 
syndrome had tuberculosis in their study (53). Due to the high HIV prevalence, the 
incidence of tuberculosis has increased in both HIV infected and uninfected individuals (52). 
There were no known HIV infected individuals in this study.  A study from India showed that 
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MCNS does occur in HIV infected individuals as well, and not all proteinuria in HIV infected 
individuals is due to HIV-associated nephropathy. They had 1 patient, out of 27 adult 
patients with renal dysfunction or nephrotic range proteinuria that had biopsy proven MCD. 
(54)  
 
4.3 Treatment 
 
4.3.1 Steroids 
 
Oral corticosteroid therapy (prednisone) was used at an initial dose of 2mg/kg/day up to a 
maximum of 60mg/day in 98% of patients. This dose is in keeping with international 
recommendations (33). The median initial duration of high dose steroids was 8 weeks with 
an interquartile range of 4 to 12 weeks after which steroids were weaned over a variable 
period. The KDIGO guidelines suggest 4 to 6 weeks of high dose steroids followed by 
alternate day steroids to be tapered over 2 to 5 months (33). This is similar to what is 
practiced elsewhere, except some use a shorter tapering period of 6 weeks (3, 14) based 
on the modified ISKDC regimen. A 2015 Cochrane Review on steroids therapy for nephrotic 
syndrome in children found that 3 newer well designed studies did not show any benefit 
from using a total of 5 to 6 months of steroid therapy versus a shorter 3 month course even 
though previous studies had shown that a longer course decreased the risk of relapses. In 
our study we found a significant association with shorter duration of steroids and the 
development of frequently relapsing nephrotic syndrome. This is in keeping with older 
studies and contrary to the findings of the Cochrane review published in 2015. The reason 
for this difference is unclear but it may be due to the difference in response to steroids in a 
different ethnic population.  They also recommended using steroids during episodes of viral 
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illnesses to decrease the risk of relapse in children with frequently relapsing nephrotic 
syndrome instead of a longer duration of initial steroids. (55)  
 
4.3.2 Other immunosuppressant agents 
 
4.3.2.1 Intravenous cyclophosphamide 
 
In our study there was a good response to monthly pulsed intravenous cyclophosphamide. 
Most patients who were previously resistant went into remission. The ISKDC reported on 
the efficacy of oral cyclophosphamide (56) in frequently relapsing nephrotic syndrome. A 
recent review reports that cyclophosphamide is still commonly used in frequently relapsing 
and steroid dependent nephrotic syndrome as a steroid sparing agent (36). Pulse 
intravenous cyclophosphamide is reported to be more effective than oral cyclophosphamide 
with fewer side effects in steroid resistant minimal change nephrotic syndrome (57).  
 
4.3.2.2 Other agents 
 
The only other agent used was oral MMF. Other centers are currently using calcineurin 
inhibitors like tacrolimus and rituximab, a monoclonal anti-CD20 antibody, as initial second 
line therapy and have shown better remission rates with them, but both these drugs are not 
easily available in our setting (36, 58). 
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4.4 Biopsy Results and Outcomes 
 
Biopsy results showed that 34% had mesangial hypercellular variant of MCD and 6% had 
IgM nephropathy. These were the only 2 variants reported on in our study, and thus the 
only 2 variants that were analysed. The ISKDC divided minimal change disease into 6 
histological subtypes, based on light microscopy. There was a significant difference in initial 
response to steroids between the “nil” disease, mild mesangial hypercellularity and diffuse 
mesangial hypercellularity but no difference in long term response to steroids at 2 years. 
(28) In this study there was no significant difference in the proportion of children with steroid 
sensitive nephrotic syndrome between the children with the mesangial hypercellular variant 
and those with just MCD (“nil” disease). Two further variants based on 
immunofluorescence, IgM nephropathy and C1q nephropathy, were initially thought to have 
a poorer prognosis than immunofluorescence-negative MCD, however, a recent study has 
shown that there is no difference in outcomes in their group of patients. (31) Both C1q and 
IgM nephropathy have been reported in a broad spectrum of glomerular diseases. (29, 31) 
In our study no patients were reported to have C1q deposits on immunofluorescence and 
6% of patients had IgM nephropathy. The group with IgM nephropathy seemed to have a 
higher rate of steroid-resistant nephrotic syndrome (43%) however, this difference was not 
significant. The lack of a significant difference may be due to the small number in this 
group. 
 
Overall the initial response to steroids was poorer than the ISKDC reports with only 67.8% 
responding to initial steroid therapy compared to 93% in their study (6). Two other South 
African studies reported an initial response rate of 68% (25) and 66% (20). There was a 
difference in the response rates between Caucasian and Black African children (81% vs 
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56%) in a study done in Pretoria (20). Other studies report on steroid response in idiopathic 
nephrotic syndrome as a whole group, which is not comparable to our study. On long term 
follow up, 28.5% of patients had steroid-resistant nephrotic syndrome, 22.3% had steroid 
dependent nephrotic syndrome and 16.1% were frequent relapsers compared to 17% 
reported previously in the same population. There is some overlap between the groups as 
some patients may have fitted into different definitions at different points in the course of 
their disease.  
 
Twenty-three of 32 patients (72%) that were treated with intravenous cyclophosphamide 
went into remission. Of the 23, 11 continued to have relapses but they were less frequent. 
In the Indian study by Elhence et al, a 100% of the children with steroid resistant minimal 
change nephrotic syndrome went into remission with intravenous cyclophosphamide. The 
numbers in this study were small and thus difficult to compare. (57) MMF has only been 
available more recently and thus there were only 8 patients treated with MMF. Only 50% of 
patients treated with MMF went into remission. An American study reported a response rate 
of 63% in steroid sensitive, frequently relapsing nephrotic syndrome and only 45% in steroid 
resistant nephrotic syndrome in a center where MMF is used as the initial second line agent 
(58) this is similar to the rate we found. The same study found a better response to 
tacrolimus (a calcineurin inhibitor) and rituximab but a poor response to cyclosporine (a 
calcineurin inhibitor) (58). Another study reported that MMF may not be as effective as 
calcineurin inhibitors in frequently relapsing nephrotic syndrome (36).   
 
A serious bacterial infection requiring hospital admission occurred in 46 patients (41%). 
This rate of infection is similar to the rate of infection (48%) found in a study done in 
Pretoria (20) looking at all children with nephrotic syndrome, and slightly higher than the 
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rate (39%)  in an Indian study which also looked at all children with nephrotic syndrome 
(53).  
 
There were 2 (1.8%) patients that demised. The ISKDC reported an overall mortality rate of 
2.5% in children with MCD. This was higher in non-responders (steroid-resistant children) 
compared to responders. (28). In our study one death occurred in the child with steroid 
resistant nephrotic syndrome and the second child was a frequent-relapser. 
 
The rate of loss to follow up was very high in this study. Twenty-nine percent defaulted 
follow up within the first year. This may affect the study findings. 
  
 39 
CHAPTER 5: CONCLUSION  
 
In our 15 year retrospective review we found some differences between our population of 
children with minimal change disease and those in the rest of the world, particularly the 
western world.  
 
The most striking differences were found in the higher proportion of children with 
haematuria and high blood pressure at presentation. There was also a poorer response to 
steroid therapy with a lower proportion of steroid responsive patients. 
  
Intravenous pulsed cyclophosphamide with or without intravenous pulsed methyl 
prednisolone was predominantly used as a second line regimen in our study. MMF was 
used in very few patients. This is different to the trend in most first world centers where 
tacrolimus and rituximab are gaining more favour. 
 
Poorer long term outcomes were predicted by steroid response rather than by histological 
variants. This seems to be in keeping with findings elsewhere. 
 
The differences between our population, which is predominantly Black African and the 
population described by most western literature, could be explained by underlying genetic 
factors which have yet to be identified. Further research is needed in this field.   
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CHAPTER 7: APPENDIX 
Appendix A: Ethics clearance certificate 
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Appendix B: Data Collection Sheet 
Study No: 
 
Sex: 
 
Age at presentation: date of presentation:   date of birth: 
 
Race: 
   
Clinical features at presentation: Weight:  Height/length:  HIV:  PPD: 
 Haematuria: 
 
 Hypertension (BP): 
 
Investigations at presentation  
 Urine protein:creatinine ratio: 
 
 Serum albumin:      Cholesterol 
  
 Renal function & GFR: 
 
Date of initial biopsy: 
 
Biopsy result: 
 
 
 
 
 
Histological Variant on electron & immunofluorescence microscopy 
 IgM nephropathy: 
 
 C1q nephropathy: 
 
 Mesangial proliferation:  
 
 
Initial Therapy:  - Steroid therapy  □ 
- Cyclophosphamide  □ 
- ACE / ARB   □  
- Spironolactone  □ 
- Salicylates / dipyridamole □ 
 
 
Duration of steroid treatment:   Relapses: 
  
 50 
Response to steroid therapy:  -    Responsive □ 
- Dependent  □ 
- Resistant  □ 
 
 
Second line therapy used: - IVI cyclophosphamide infusion  □ 
    - Additional IVI methyl prednisolone □ 
    - Oral MMF     □ 
 
 
Repeat biopsy performed:  Y / N  
 
Date of repeat biopsy: 
 
Result of repeat biopsy: 
 
 
 
 
 
 
 
 
Follow up: 
 Outcome at 1 year:  
 
 
 
 
 Length of follow up: 
 
 In remission Y/N 
 
 Steroid dependence Y/N 
 
 Renal Failure  Y/N 
 
 Other complications:  
- Hypertension: Y/N 
- Infections (pneumonia/ peritonitis/ septicaemia/ other): Y/N 
- Cataracts 
 
Lost to follow up: Y/N 
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Appendix C: Turnitin  
 
